How does COVID-19 affect the HCPS relationships with patients and with the pharmaceutical industry? The results of the 2nd phase of our syndicated Covid-19 impact study are available this month for the French market.
Understand the past and expected evolutions of the remote mode for patient consultations, medical and sales reps promotion, or attending medical conferences or local meetings, all analyzed among various specialties: General Practitioners, Oncologists, Onco-hematologists, Hematologists, Psychiatrists, Urologists, Dermatologists, Cardiologists, Gastroenterologists, Pneumologists, Rheumatologists.
Did you know? A decrease experienced by 81%
In October 2020, 81% of Onco-hematologists noted a decrease in promotion by medical sales representatives compared to the pre-crisis Covid period, mainly attributed to the pharma companies for 9 out of 10, while marking their clear preference for face-to-face meetings (two thirds of doctors). No return to normal is foreseen before a vaccine is available according to 1 in 2 doctors.
Last spring, the proportion of Onco-hematologists accepting a distant medical sales rep visit remained low, at 39%, and just under 1 in 2 remained opposed to distant visits once lockdown would be over.
Source: example of result from AplusA syndicated study “Impact of Covid-19 on medical practices in France”: excerpt from a national representative sample of onco-hematologists surveyed in Oct-November and previously May-June 2020. Other data and specialties available.
If you want to know more, the results of both phases are available from a large panel of specialties interviewed in France in spring and again this fall (General practitioners, Oncologists, Onco-hematologists, Hematologists, Psychiatrists, Urologists, Dermatologists, Cardiologists, Gastroenterologists, Pneumologists, Rheumatologists, ...).
Teleconsultations' Impact
Did you know? 11% teleconsultations
In October 2020, 62% of Onco-hematologists have performed at least one teleconsultation, bringing the share of teleconsultations to 11% of consultations (compared to 6% before the Covid crisis and 55% at its peak in the spring). In total, a small majority of Onco-hematologists say they are satisfied (56%).
Last spring, however, the Onco-hematologists surveyed expected a more marked increase in the share of teleconsultations in their activity, up to 22%. This compares to their highest satisfaction level of 72%.
Source: example of results from our AplusA syndicated study "Impact of Covid-19 on medical practices in France": analysis extracted from the results observed on a representative sample of onco-hematologists interviewed in October-Nov and previously May-June 2020. Many other data and specialties are available. For example, our results show the impact on the type of management and preferred treatment options, particularly in Multiple Myeloma and CLL, and the impact on the frequency of diagnostic and follow-up visits.
If you want to know more, the results of both phases are available in the form of a syndicated study conducted among a large panel of specialties surveyed in France in the spring and again this fall (General Practitioners, Oncologists, Onco-hematologists, Hematologists, Psychiatrists, Urologists, Dermatologists, Cardiologists, Gastroenterologists, Pneumologists, Rheumatologists, ...).
Medical Congress
Did you know that 25% of our clients prefer to distance themselves from their customers?
From May to October 2020, 63% of Onco-hematologists attended at least one medical congress, but only 17% in person. The distant congresses still segment the onco-hematologists, with only one out of 2 satisfied with what is offered. And in the future, 60% will prefer face-to-face meetings if they have the choice, but 25% will prefer remote meetings to meet the current ecological challenges and save time.
Source: example of results from our AplusA syndicated study "Impact of Covid-19 on medical practices in France": analysis extracted from the results observed on a representative sample of onco-hematologists interviewed in October-November 2020. Many other data and specialties are available.
If you want to know more, the results of both phases are available in the form of a syndicated study conducted among a large panel of specialties interviewed in France in spring and again this fall (General practitioners, Oncologists, Onco-hematologists, Hematologists, Psychiatrists, Urologists, Dermatologists, Cardiologists, Gastroenterologists, Pneumologists, Rheumatologists, ...).